Oral delivery of biologics presents a formidable challenge: achieving high bioavailability without compromising gastrointestinal barrier integrity or clinical scalability-a trilemma that remains unaddressed by existing chemical permeation enhancers, ligand-modified nanoparticles, or exosome platforms. Here, we repurpose β-lactoglobulin (BLG) nanofibrils that resolve this challenge through a unique "enhance-degrade-restore" mechanism. In vivo, these nanofibrils enable oral insulin bioavailability reaching 10.2-12.3 %, and long-term safety studies confirm the absence of intestinal damage. Mechanistic studies reveal that the nanofibrils facilitate Ca²⁺ influx-induced calpain activation to enhance paracellular permeability, followed by protease-mediated degradation that ensures timely restoration of barrier integrity. Moreover, nanofibrils maintain full adjuvant activity when integrated into commercial milk products, highlighting their formulation flexibility and robustness. This work introduces a sustainable "waste-to-nanomedicine" strategy that unites high-efficiency peptide delivery with environmentally responsible nanomaterial design.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: